Tech Company Financing Transactions

Galecto Funding Round

Eir Ventures, Soleus Capital and Asymmetry Capital Management participated in a $64 million funding round for Galecto. The funding round closed on 9/28/2020.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

Ole Maaloes Vej 3
Copenhagen, DK-2200
Denmark

Phone

+45 70 70 52 10

Website

www.galecto.com

Email Address

[email protected]

Overview

Galecto (Nasdaq: GLTO) is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Hans Schambye

        

Chief Financial Officer

Jonathan Freve

        

Chief Marketing Officer

Bertil Lindmark

        

Chief Operating Officer

Anders Pedersen

        

Browse more venture capital transactions:

Prev: 9/28/2020: NeuroTherapia venture capital transaction
Next: 9/28/2020: GOAT venture capital transaction

Share this article

About Database of VC Transactions

We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary